Abstract
ABSTRACTPseudomonas aeruginosais a common nosocomial pathogen and a major cause of morbidity and mortality in hospitalized patients. Multiple reports highlight thatP. aeruginosagastrointestinal colonization may precede systemic infections by this pathogen. Gaining a deeper insight into the dynamics ofP. aeruginosagastrointestinal carriage is an essential step in managing gastrointestinal colonization and could contribute to preventing bacterial transmission and progression to systemic infection. Here, we present a clinically relevant mouse model relying on parenteral vancomycin pretreatment and a single orogastric gavage of a controlled dose ofP. aeruginosa.Robust carriage was observed with multiple clinical isolates, and carriage persisted for up to 60 days. Histological and microbiological examination of mice indicated that this model indeed represented carriage and not infection. We then used a barcodedP. aeruginosalibrary along with the sequence tag-based analysis of microbial populations (STAMPR) analytic pipeline to quantify bacterial population dynamics and bottlenecks during the establishment of the gastrointestinal carriage. Analysis indicated that most of theP. aeruginosapopulation was rapidly eliminated in the stomach, but the few bacteria that moved to the small intestine and the caecum expanded significantly. Hence, the stomach constitutes a significant barrier against gastrointestinal carriage ofP. aeruginosa,which may have clinical implications for hospitalized patients.IMPORTANCEWhileP. aeruginosais rarely part of the normal human microbiome, carriage of the bacterium is quite frequent in hospitalized patients and residents of long-term care facilities.P. aeruginosacarriage is a precursor to infection. Options for treating infections caused by difficult-to-treatP. aeruginosastrains are dwindling, underscoring the urgency to better understand and impede pre-infection stages, such as colonization. Here, we use vancomycin-treated mice to model antibiotic-treated patients who become colonized withP. aeruginosain their gastrointestinal tracts. We identify the stomach as a major barrier to the establishment of gastrointestinal carriage. These findings suggest that efforts to prevent gastrointestinal colonization should focus not only on judicious use of antibiotics but also on investigation into how the stomach eliminates orally ingestedP. aeruginosa.
Publisher
Cold Spring Harbor Laboratory
Reference66 articles.
1. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019;The Lancet,2022
2. Centers for the Disease Control and Prevention. 2023. Pseudomonas aeruginosa Infection HAI CDC. https://www.cdc.gov/hai/organisms/pseudomonas.html. Retrieved 8 March 2024.
3. Multistate Point-Prevalence Survey of Health Care–Associated Infections
4. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
5. Centers for Disease Control and Prevention (U.S.). 2019. Antibiotic resistance threats in the United States, 2019. Centers for Disease Control and Prevention (U.S.).